AbTis specializes in antibody-drug conjugation (ADC) technology, utilizing a proprietary linker platform to enhance the efficacy and solubility of therapeutic antibodies. This technology addresses the challenges of delivering potent drugs to target cells while minimizing off-target effects, improving treatment outcomes in cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody-drug conjugates (ADCs) often suffer from issues related to drug delivery, off-target effects, and limited solubility, which can hinder their efficacy in cancer treatment. These challenges can lead to suboptimal therapeutic outcomes and increased toxicity.
Solution
AbTis is developing a proprietary linker platform for antibody-drug conjugates (ADCs) designed to improve the delivery of potent drugs to target cells while minimizing off-target effects. This technology aims to enhance the efficacy and solubility of therapeutic antibodies, leading to improved treatment outcomes in cancer therapies. By optimizing the linker, AbTis seeks to create ADCs with enhanced stability, reduced systemic toxicity, and improved tumor penetration. The platform is intended to address the limitations of existing ADC technologies, offering a more targeted and effective approach to cancer treatment.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions involved in the development of novel cancer therapies, as well as patients who may benefit from more effective and targeted cancer treatments.
Features
- Proprietary linker technology designed for enhanced ADC stability and solubility.
- Focus on minimizing off-target effects to reduce toxicity.
- Platform aimed at improving drug delivery to target cells.
- Development of ADCs for cancer therapies.